Activ8rlives 3.0 Health and Food Diary Self-Monitoring App for iOS and Android Released

Press release   •   Mar 12, 2015 17:04 GMT

New trackers are now standard, new graphing, new device integration and colour-coding to enable the user to quickly understand where a health tracker or vital sign should be to indicate good health.
Activ8rlives 3.0 Health and Food Diary App works with a full range of consumer and medical devices. Data is stored and can be shared with family supporters or carers online. Those who wish to can also share their data with their medical staff using a dedicated clinician’s portal.
The new Activ8rlives 3.0 Health and Food Diary App has been completely rewritten from the ground-up. This has accelerated the speed at which it processes and displays the increasing amount of information that the user can collect. It has greatly enhanced the quality of the user experience and has added a trend-setting level of support and education about health, enabling the user to learn how to monitor their own vital signs and how to interpret them.

Restructuring the App is in preparation for CE marking as a certified medical device (initially Class 1). Data generated by the user and stored within Activ8rlives can then be accepted by clinicians World-over and used in partnership with their patients in support of self-management programmes.
This development also prepares for the integration of the Company’s third generation of medical monitors such as the BuddyWOTCHTM and the EyKosTM home hub system, in which patients with Long-Term Conditions will be warned of an impending respiratory failure and the flare-up (exacerbation) of chest infections. The integration, validation and certification of the complete solutions as a medical device, is becoming increasingly important as healthcare providers begin adopting new technologies driven by escalating demand.

Part of Activ8rlives’ restructuring builds in future capability to seamlessly bring information into and out of it (interoperability) so that information can be exchanged with other software selected by the user. This will soon include the ability to share data with Apple’s iPhone-based HealthKitTM, Samsung’s S HealthTM online platform and the UK’s NHS data systems as the standards for data exchange and information security are defined by the NHS throughout 2015/2016.

It also paves the way for Activ8rlives to merge medical data from NHS systems so that lay people can understand this information.

Kevin A. Auton, Ph.D., Founder and Managing Director of Aseptika Ltd, said of the new version:
“Data generated by users of Activ8rlives belongs to the user. What we choose to do with this
Activ8rlives is a Trademark of Aseptika Ltd: 14 Elizabeth Drive, Hartford, Huntingdon, Cambridgeshire PE29 1WA, UK

- Ends -

Caption: The newly launched Activ8rlives 3.0 Health and Food Diary Self-Monitoring App for iOS and select Android Smartphones and Tablets.

Notes: Part funding from the European Regional Development Fund was made available for this redevelopment of the Activ8rlives App 3.0 under the ERDF MedTech Low Carbon Innovation Programme.

About Aseptika Limited (Activ8rlives): Aseptika Limited is a healthcare company developing and marketing an integrated suite of self-monitoring devices and services under the Activ8rlives brand. We are developing integrated systems which can be used by laypeople and their healthcare service providers to better self-manage long-term health conditions (LTHC) through self-monitoring. The Company’s goal is to provide everyone with tools (and the understanding of how to apply them) so that most of us can keep healthy and well for most of the time. Self-management through self-monitoring is the motivation driving what we do. Activ8rlives is unusual in that we are device agnostic, incorporating sensors and monitors ranging from consumer accessories to in vitro diagnostics (IVDs) with a focus on respiratory disease. All data is held together and can be cross analysed in the Cloud to provide forecasts and learning for the user and clinician. The Company gained a patent in 2013 protecting the invention of a test for biomarkers of Pseudomonas aeruginosa (PA) in the sputum of patients, which can be used to detect the on-set of an exacerbation and profile the efficacy of antibiotic treatment for each patient. Aseptika won first place in a competition earlier in 2014 to reward the most “Promising eHealth EU SME” eHealth solution 2014 developed by an early-stage European SME. The 2014 Competition was organized by TICBioMed and had the endorsement of the Health and Wellbeing Unit of DG CONNECT of the 

European Commission. The judges commended Aseptika for the integrated approach it was taking in the support of patients with long-term respiratory disease, providing the platform to self-manage their illness through self-monitoring. Central to the Company’s “hospital-at-home” concept, is a test in which the patient measures the level of virulence of the bacteria living in their lungs which from time to time, flare into a full and repeated chest infections.

Aseptika was a shortlisted finalist for the Cambridge News Top Innovations 2014 and AXA PPP Health Tech & You Awards. Winner of the Discovery Start-up 2014 Competition run by Cambridge Wireless and Winner of the Hunts Post Huntingdonshire Business Innovation Awards 2014. Named on Global Digital Health 100 Award list, reflecting the importance of mobile and digital solutions.
Activ8rlives is a Trademark of Aseptika Ltd: 14 Elizabeth Drive, Hartford, Huntingdon, Cambridgeshire PE29 1WA, UK

Tel: +44 (0)1480 352 821
Company Registered in England No. 06425174 VAT Registered 985 5533 73
Wearable Technology Awards 2015 shortlisted Aseptika in three categories: Best Medical Device, Best Innovation and Overall Wearable Winner.
For more information on Aseptika Ltd, Activ8rlives and products, please visit:
Activ8rlives,, BuddyWOTCH and EyKos are trademarks of Aseptika Ltd.

For press information, please contact:
Jessica Auton, Marketing Director
Direct +44 (0)1480 352 821
Mobile +44 (0)7455 922 122
Kimberley Huggins, PR Manager
Direct +44 (0)1480 352 821
A8119 v Final